President Donald Trump has placed special emphasis on reversing initiatives directly associated with his predecessor, but one important Obama era executive order for the biopharma sector has – so far at least – remained in effect: the initiative to combat antibiotic resistance.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?